Codexis amd Arch Pharmalabs achieve development milestone
Advertisement
Codexis, Inc. announced it has achieved an important development milestone under a research and manufacturing agreement with Arch Pharmalabs, Ltd. Arch has successfully integrated Codexis' ThoroughBred(TM) biological catalysts and proprietary biocatalytic system into commercial production of a key intermediate used in the manufacture of a high-value pharmaceutical active pharmaceutical ingredient (API). Arch will continue to scale-up the manufacturing process and provide commercial quantities of the intermediate.
Under terms of the agreement announced in October 2005, achievement of the milestone triggers an undisclosed payment to Codexis. Further terms were not announced.